Blog

• Revenue growth of 5%
• Continuous strong growth in theranostics sales: +27%
• Theranostics revenues up to 50% of total sales

Croissy-Beaubourg and Montpellier, April 27, 2017, 8:00am CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME plans), a company specialized in in vitro diagnostics and theranostics, has today announced its consolidated first-quarter 2017 revenues.

In the first quarter of 2017, Theradiag posted a 5% increase in its consolidated revenues to €2.3 million.

During the period, the Theranostics BU’s sales rose 27% to €1.1 million, and these now account for 50% of total revenues. Sales of other IVD products declined 10% pending the launch of the new BioCLIA IVD range.

International sales came to €1.2 million, and these accounted for 50% of total revenues.

Michel Finance, Chief Executive Officer of Theradiag, commented: “Lisa Tracker® sales now account for 50% of our revenues, following a sharp increase of 27% versus the first quarter of 2016. This growth is a ringing endorsement of Theradiag’s strategy focused on theranostics in France and international markets, especially in the United States, under our partnership with Miraca Life Sciences, as demonstrated by the recent launch of a sixth test. This year, we intend to launch the BioCLIA range with HOB Biotech, our Chinese partner, to accelerate this growth in the Lisa Tracker® range and inject fresh impetus into our IVD sales. That should deliver strong growth in our business during 2017.”

Next financial press release:

2017 First-half sales: Tuesday July 25, 2017

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com